Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bella R, Zinnatulina"'
Autor:
Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1337-1347
Aim: To evaluate the safety and efficacy of insulin Aspart-Mix biosimilar candidate GP40081 (GP-Asp30) compared with NovoMix ® 30 (NN-Asp30). Materials & methods: In a randomized open-label, active-controlled, 26-week non-inferiority clinical trial
Autor:
Victoria S, Kulesh, Roman V, Drai, Bella R, Zinnatulina, Igor E, Makarenko, Fedor G, Pilyus, Alexander L, Khokhlov
Publikováno v:
The Journal of Clinical Pharmacology. 62:1086-1093
This study includes modeling and simulation of insulin aspart pharmacokinetics (PK). The authors used PK data of biosimilar insulins-insulin aspart and biphasic insulin aspart 30/70-to develop a predictive population PK model for the insulins. The mo
Autor:
Roman V, Drai, Alexander Y, Mayorov, Tatiana L, Karonova, Tatiana M, Parfenova, Igor E, Makarenko, Maxim A, Magruk, Diana N, Alpenidze, Vladislav V, Kovalik, Bella R, Zinnatulina, Irina V, Grigorjeva, Alena T, Andreeva
Publikováno v:
Journal of comparative effectiveness research.
Autor:
Aleksandr V. Petrov, Bella R. Zinnatulina, Roman V. Drai, Tatiana L. Karonova, Ekaterina O. Koksharova, Artem R. Dorotenko, Igor E. Makarenko
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(12)
This paper presents an analysis of data from a comparative study of biosimilarity in terms of pharmacokinetics and pharmacodynamics in healthy volunteers using a hyperinsulinemic euglycemic clamp for reference and test biphasic insulin aspart 30 (BIA
Autor:
Maria V Verbovaya, Ivan S Lunev, Anna A Mosikian, Bella R Zinnatulina, Alexandr Y Mayorov, Diana N Alpenidze, Igor E. Makarenko, Roman V. Drai, Alexander L Khokhlov, Valeria L Orlova
Publikováno v:
Journal of Comparative Effectiveness Research. 10:55-66
Aim: To compare safety (immunogenicity) and efficacy of a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25) in Type 2 diabetes mellitus (T2D) patients. Materials & methods: This randomized open-label, 26-week clinical tria